Drug screening of cancer cell lines and human primary tumors using droplet microfluidics

Abstract Precision Medicine in Oncology requires tailoring of therapeutic strategies to individual cancer patients. Due to the limited quantity of tumor samples, this proves to be difficult, especially for early stage cancer patients whose tumors are small. In this study, we exploited a 2.4 × 2.4 ce...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ada Hang-Heng Wong, Haoran Li, Yanwei Jia, Pui-In Mak, Rui Paulo da Silva Martins, Yan Liu, Chi Man Vong, Hang Cheong Wong, Pak Kin Wong, Haitao Wang, Heng Sun, Chu-Xia Deng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/09904b3aa3004ace89370e211250ec32
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:09904b3aa3004ace89370e211250ec32
record_format	dspace
spelling	oai:doaj.org-article:09904b3aa3004ace89370e211250ec322021-12-02T11:52:26ZDrug screening of cancer cell lines and human primary tumors using droplet microfluidics10.1038/s41598-017-08831-z2045-2322https://doaj.org/article/09904b3aa3004ace89370e211250ec322017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-08831-zhttps://doaj.org/toc/2045-2322Abstract Precision Medicine in Oncology requires tailoring of therapeutic strategies to individual cancer patients. Due to the limited quantity of tumor samples, this proves to be difficult, especially for early stage cancer patients whose tumors are small. In this study, we exploited a 2.4 × 2.4 centimeters polydimethylsiloxane (PDMS) based microfluidic chip which employed droplet microfluidics to conduct drug screens against suspended and adherent cancer cell lines, as well as cells dissociated from primary tumor of human patients. Single cells were dispersed in aqueous droplets and imaged within 24 hours of drug treatment to assess cell viability by ethidium homodimer 1 staining. Our results showed that 5 conditions could be screened for every 80,000 cells in one channel on our chip under current circumstances. Additionally, screening conditions have been adapted to both suspended and adherent cancer cells, giving versatility to potentially all types of cancers. Hence, this study provides a powerful tool for rapid, low-input drug screening of primary cancers within 24 hours after tumor resection from cancer patients. This paves the way for further technological advancement to cutting down sample size and increasing drug screening throughput in advent to personalized cancer therapy.Ada Hang-Heng WongHaoran LiYanwei JiaPui-In MakRui Paulo da Silva MartinsYan LiuChi Man VongHang Cheong WongPak Kin WongHaitao WangHeng SunChu-Xia DengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-15 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ada Hang-Heng Wong Haoran Li Yanwei Jia Pui-In Mak Rui Paulo da Silva Martins Yan Liu Chi Man Vong Hang Cheong Wong Pak Kin Wong Haitao Wang Heng Sun Chu-Xia Deng Drug screening of cancer cell lines and human primary tumors using droplet microfluidics
description	Abstract Precision Medicine in Oncology requires tailoring of therapeutic strategies to individual cancer patients. Due to the limited quantity of tumor samples, this proves to be difficult, especially for early stage cancer patients whose tumors are small. In this study, we exploited a 2.4 × 2.4 centimeters polydimethylsiloxane (PDMS) based microfluidic chip which employed droplet microfluidics to conduct drug screens against suspended and adherent cancer cell lines, as well as cells dissociated from primary tumor of human patients. Single cells were dispersed in aqueous droplets and imaged within 24 hours of drug treatment to assess cell viability by ethidium homodimer 1 staining. Our results showed that 5 conditions could be screened for every 80,000 cells in one channel on our chip under current circumstances. Additionally, screening conditions have been adapted to both suspended and adherent cancer cells, giving versatility to potentially all types of cancers. Hence, this study provides a powerful tool for rapid, low-input drug screening of primary cancers within 24 hours after tumor resection from cancer patients. This paves the way for further technological advancement to cutting down sample size and increasing drug screening throughput in advent to personalized cancer therapy.
format	article
author	Ada Hang-Heng Wong Haoran Li Yanwei Jia Pui-In Mak Rui Paulo da Silva Martins Yan Liu Chi Man Vong Hang Cheong Wong Pak Kin Wong Haitao Wang Heng Sun Chu-Xia Deng
author_facet	Ada Hang-Heng Wong Haoran Li Yanwei Jia Pui-In Mak Rui Paulo da Silva Martins Yan Liu Chi Man Vong Hang Cheong Wong Pak Kin Wong Haitao Wang Heng Sun Chu-Xia Deng
author_sort	Ada Hang-Heng Wong
title	Drug screening of cancer cell lines and human primary tumors using droplet microfluidics
title_short	Drug screening of cancer cell lines and human primary tumors using droplet microfluidics
title_full	Drug screening of cancer cell lines and human primary tumors using droplet microfluidics
title_fullStr	Drug screening of cancer cell lines and human primary tumors using droplet microfluidics
title_full_unstemmed	Drug screening of cancer cell lines and human primary tumors using droplet microfluidics
title_sort	drug screening of cancer cell lines and human primary tumors using droplet microfluidics
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/09904b3aa3004ace89370e211250ec32
work_keys_str_mv	AT adahanghengwong drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT haoranli drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT yanweijia drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT puiinmak drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT ruipaulodasilvamartins drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT yanliu drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT chimanvong drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT hangcheongwong drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT pakkinwong drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT haitaowang drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT hengsun drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics AT chuxiadeng drugscreeningofcancercelllinesandhumanprimarytumorsusingdropletmicrofluidics
_version_	1718395028130234368

Drug screening of cancer cell lines and human primary tumors using droplet microfluidics

Ejemplares similares